Zymeworks Inc (ZYME)

Apr 21, 2025, 6:00 AM EDT - 2 days ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 17, 2025, 6:00 AM EDT - 6 days ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 26, 2025, 6:00 AM EDT - 4 weeks ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Mar 25, 2025, 4:30 PM EDT - 4 weeks ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 6, 2025, 1:18 PM EST - 6 weeks ago

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Mar 5, 2025, 8:43 PM EST - 7 weeks ago

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 4:05 PM EST - 7 weeks ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 6:00 AM EST - 2 months ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 18, 2025, 6:00 AM EST - 2 months ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 13, 2025, 6:00 AM EST - 2 months ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Jan 22, 2025, 12:29 PM EST - 3 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ ONC XBI

Jan 8, 2025, 4:05 PM EST - 3 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Dec 19, 2024, 9:00 AM EST - 4 months ago

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Nov 21, 2024, 6:00 AM EST - 5 months ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 5, 2024, 6:00 AM EST - 6 months ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Nov 4, 2024, 4:28 AM EST - 6 months ago

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Oct 31, 2024, 10:05 PM EDT - 6 months ago

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Oct 25, 2024, 6:00 AM EDT - 6 months ago

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Oct 21, 2024, 6:00 AM EDT - 6 months ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Oct 10, 2024, 6:30 AM EDT - 6 months ago

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Sep 27, 2024, 2:47 PM EDT - 7 months ago

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 18, 2024, 6:00 AM EDT - 7 months ago

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Sep 3, 2024, 4:30 PM EDT - 8 months ago

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Aug 1, 2024, 10:58 PM EDT - 9 months ago

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:10 PM EDT - 9 months ago

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

Jul 25, 2024, 4:30 PM EDT - 9 months ago

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

Jul 22, 2024, 6:00 AM EDT - 9 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

Jul 11, 2024, 6:30 AM EDT - 10 months ago

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

Jun 17, 2024, 6:00 AM EDT - 11 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

Jun 10, 2024, 6:00 AM EDT - 11 months ago

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

May 2, 2024, 8:04 PM EDT - 1 year ago

Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 3:06 PM EDT - 1 year ago

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data